 Bezafibrate
"Bezafibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
| Descriptor ID |
D001629
|
| MeSH Number(s) |
D02.065.277.067 D02.241.081.160.700.500.249 D02.241.223.100.120.101 D02.355.726.305.249 D02.755.654.305.249
|
| Concept/Terms |
Befibrat- Befibrat
- Hennig Brand of Bezafibrate
- Bezafibrate Hennig Brand
Beza-Lande- Beza-Lande
- Beza Lande
- BezaLande
- Synthelabo Brand of Bezafibrate
- Bezafibrate Synthelabo Brand
Beza-Puren- Beza-Puren
- Beza Puren
- BezaPuren
- Isis Brand of Bezafibrate
- Bezafibrate Isis Brand
Bezabeta- Bezabeta
- Betapharm Brand of Bezafibrate
- Bezafibrate Betapharm Brand
Bezacur- Bezacur
- Hexal Brand of Bezafibrate
- Bezafibrate Hexal Brand
Bezafibrat PB- Bezafibrat PB
- PB, Bezafibrat
- Teva Brand of Bezafibrate
- Bezafibrate Teva Brand
Bezafisal- Bezafisal
- Cryopharma Brand of Bezafibrate
- Bezafibrate Cryopharma Brand
Bezalip- Bezalip
- Eulitop
- Lakeside Brand of Bezafibrate
- Bezafibrate Lakeside Brand
- Boehringer Mannheim Brand of Bezafibrate
Cedur- Cedur
- Difaterol
- Roche Brand of Bezafibrate
- Bezafibrate Roche Brand
- Béfizal
Lipox- Lipox
- TAD Brand of Bezafibrate
- Bezafibrate TAD Brand
Reducterol- Reducterol
- Elfar Brand of Bezafibrate
- Bezafibrate Elfar Brand
Regadrin B- Regadrin B
- Berlin-Chemie Brand of Bezafibrate
- Berlin Chemie Brand of Bezafibrate
- Bezafibrate Berlin-Chemie Brand
Sklerofibrat- Sklerofibrat
- Merckle Brand of Bezafibrate
- Bezafibrate Merckle Brand
Solibay- Solibay
- Bayer Brand of Bezafibrate
- Bezafibrate Bayer Brand
Azufibrat- Azufibrat
- Azupharma Brand of Bezafibrate
- Bezafibrate Azupharma Brand
|
Below are MeSH descriptors whose meaning is more general than "Bezafibrate".
Below are MeSH descriptors whose meaning is more specific than "Bezafibrate".
This graph shows the total number of publications written about "Bezafibrate" by people in this website by year, and whether "Bezafibrate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Bezafibrate" by people in Profiles.
-
Davidson MH. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
-
Perkins JD. Saying "Yes" to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Liver Transpl. 2006 Jun; 12(6):1012-3.
-
Davidoff AJ, Mason MM, Davidson MB, Carmody MW, Hintz KK, Wold LE, Podolin DA, Ren J. Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab. 2004 May; 286(5):E718-24.
-
Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001 Apr; 50(4):477-80.
-
Fukushima M, Taniguchi A, Sakai M, Doi K, Nagata I, Nagasaka S, Tokuyama K, Nakai Y. Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care. 2000 Feb; 23(2):259.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|